HBV FORUM 3

Tuesday, October 24th, 2017
Marriott Marquis
Washington, DC
1:30 pm - 6:30 pm US-ET
AGENDA

12:30	**Light Lunch Reception**		13:00
1:30	1. Welcoming Remarks	Veronica Miller Pedro Goicochea	0:15
1:45	2. Current FDA Perspective on HBV Drug Development	Poonam Mishra	0:15
2:00	3. FDA Perspective on HBV Diagnostic Devices	Kathleen Whitaker	0:15
2:15	4. Quantitative Serum HBsAg Assay Validation for U.S. Patient Testing	Robert Gish	0:15
2:30	5. Implications of HBsAg from Integrated DNA for Clinical Trial Design	Bruce Given	0:15
2:45	6. HBV Next Generation Sequencing	Leen-Jan van Doorn	0:15
3:00	7. Panel discussion	Timothy Block Carol Brosgart Anuj Gaggar Edward Gane Maureen Kamischke	0:40
3:40	**Break**		0:20
4:00	8. Diagnostics and Biomarkers Working Group Updates - Achievements	Ed Marins Gavin Cloherty	0:10
4:10	Discussion	All	0:10
4:20	9. Surrogate Endpoints Working Group Updates - Achievements - Updates on Collaboration with Other Stakeholders - Next Steps	Oliver Lenz	0:20
4:40	Discussion	All	0:10
4:50	10. Treatment Combination Working Group Updates - Achievements - Recommendations: Position Paper - Next Steps	Bruce Given Seng Gee Lim	0:20
5:10	Discussion	All	0:10
5:20	11. Road Map of Research Priorities for HBV Cure	Tim Block	0:10
5:30	Discussion	All	0:10
5:40	12. International Coalition to Eliminate HBV	Peter Revill	0:30
6:10	Discussion	All	0:10
6:20	13. Wrap up	Veronica Miller	0:10
6:30	**Networking Reception**		1:00
7:30	**Adjourn**		

v. 1.0 - 23OCT17